Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine

ClinicalTrials.gov ID: NCT04164758

Public ClinicalTrials.gov record NCT04164758. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 25, 2026, 8:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Pilot Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine

Study identification

NCT ID
NCT04164758
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Enrollment
11 participants

Conditions and interventions

Interventions

  • Pimavanserin Drug
  • Placebo Other
  • Quetiapine Drug

Drug · Other

Eligibility (public fields only)

Age range
50 Years to 85 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 22, 2019
Primary completion
Sep 24, 2020
Completion
Sep 24, 2020
Last update posted
Oct 13, 2021

2019 – 2020

United States locations

U.S. sites
16
U.S. states
11
U.S. cities
16
Facility City State ZIP Site status
Movement Disorders Center of Arizona Scottsdale Arizona 85258
Tucson Neuroscience Research Tucson Arizona 85710
Sutter Institute for Medical Research Sacramento California 95816
Galiz Research Hialeah Florida 30016
Charter Research, LLC Lady Lake Florida 32159
Premier Clinical Research Institute, Inc. Miami Florida 33122
Infinity Clinical Research, LLC Sunrise Florida 33351
Charter Research, LLC Winter Park Florida 32792
Meridian Clinical Research Savannah Georgia 31406
Hawaii Pacific Neuroscience, LLC. Honolulu Hawaii 96817
University of lowa Hospital and Clinics Iowa City Iowa 52242
SRI International Plymouth Michigan 48170
Bio Behavioral Health Toms River New Jersey 08755
M3 Wake Research, Inc. Raleigh North Carolina 27612
Dayton Center for Neurological Disorders Centerville Ohio 45459
Prisma Health-Upstate Greenville South Carolina 29615

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04164758, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 13, 2021 · Synced Jun 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04164758 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →